Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
FY Pharmaceuticals sales grew +7%, growth drivers represent 52%
Pharmaceuticals net sales
USD bn, % cc
Q4
+9%1
FY
+7%
26.5
6.8
6.4
24.3
+28%
+30%
2.9
3.7
13.7
Representing
10.5
Representing
54% of sales
52% of sales
3.5
3.1
-7%
Q4 2020
Q4 2021
13.8
- -9%
12.8
FY 2020
FY 2021
Growth drivers²
Mature products³
All % growth relate to cc unless otherwise stated. 1. Q4 sales growth for Pharmaceuticals includes +2% points impact from a reclassification of contract manufacturing from other revenue to sales. 2. ZolgensmaⓇ, KesimptaⓇ, MayzentⓇ,
BeovuⓇ, Luxturna®, Leqvio®, Enerzair® and Atectura®, Cosentyx®, Entresto®, Xolair®, Ilaris®, XiidraⓇ and AimovigⓇ. 3. All other brands.
25 Investor Relations | Q4 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation